Your browser doesn't support javascript.
loading
Phenotype of CM-AVM2 caused by variants in EPHB4: how much overlap with hereditary hemorrhagic telangiectasia (HHT)?
Wooderchak-Donahue, Whitney L; Akay, Gulsen; Whitehead, Kevin; Briggs, Eric; Stevenson, David A; O'Fallon, Brendan; Velinder, Matthew; Farrell, Andrew; Shen, Wei; Bedoukian, Emma; Skrabann, Cara M; Antaya, Richard J; Henderson, Kate; Pollak, Jeffrey; Treat, James; Day, Ronald; Jacher, Joseph E; Hannibal, Mark; Bontempo, Kelly; Marth, Gabor; Bayrak-Toydemir, Pinar; McDonald, Jamie.
Affiliation
  • Wooderchak-Donahue WL; ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA.
  • Akay G; Department of Pathology, University of Utah, Salt Lake City, UT, USA.
  • Whitehead K; ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA.
  • Briggs E; Zeynep Kamil Training and Research Hospital, Istanbul, Turkey.
  • Stevenson DA; Division of Cardiovascular Medicine, Department of Medicine, HHT Center, University of Utah, Salt Lake City, UT, USA.
  • O'Fallon B; ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA.
  • Velinder M; Division of Medical Genetics, Department of Pediatrics, Stanford University, Stanford, CA, USA.
  • Farrell A; ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA.
  • Shen W; USTAR Center for Genetic Discovery, University of Utah, Salt Lake City, UT, USA.
  • Bedoukian E; USTAR Center for Genetic Discovery, University of Utah, Salt Lake City, UT, USA.
  • Skrabann CM; ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA.
  • Antaya RJ; Roberts Individualized Medical Genetics Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Henderson K; Roberts Individualized Medical Genetics Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Pollak J; Division of Human Genetics, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Treat J; Departments of Dermatology and Pediatrics and HHT Program, Yale University School of Medicine, New Haven, CT, USA.
  • Day R; Department of Radiology and Biomedical Imaging, and HHT Program, Yale University School of Medicine, New Haven, CT, USA.
  • Jacher JE; Department of Radiology and Biomedical Imaging, and HHT Program, Yale University School of Medicine, New Haven, CT, USA.
  • Hannibal M; Dematology Section, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Bontempo K; Division of Pediatric Cardiology, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
  • Marth G; Department of Pediatrics and Communicable Diseases, Division of Pediatric Genetics, Metabolism &Genomic Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Bayrak-Toydemir P; Department of Pediatrics and Communicable Diseases, Division of Pediatric Genetics, Metabolism &Genomic Medicine, University of Michigan, Ann Arbor, MI, USA.
  • McDonald J; Advocate Children's Hospital, Park Ridge, IL, USA.
Genet Med ; 21(9): 2007-2014, 2019 09.
Article in En | MEDLINE | ID: mdl-30760892
ABSTRACT

PURPOSE:

EPHB4 variants were recently reported to cause capillary malformation-arteriovenous malformation 2 (CM-AVM2). CM-AVM2 mimics RASA1-related CM-AVM1 and hereditary hemorrhagic telangiectasia (HHT), as clinical features include capillary malformations (CMs), telangiectasia, and arteriovenous malformations (AVMs). Epistaxis, another clinical feature that overlaps with HHT, was reported in several cases. Based on the clinical overlap of CM-AVM2 and HHT, we hypothesized that patients considered clinically suspicious for HHT with no variant detected in an HHT gene (ENG, ACVRL1, or SMAD4) may have an EPHB4 variant.

METHODS:

Exome sequencing or a next-generation sequencing panel including EPHB4 was performed on individuals with previously negative molecular genetic testing for the HHT genes and/or RASA1.

RESULTS:

An EPHB4 variant was identified in ten unrelated cases. Seven cases had a pathogenic EPHB4 variant, including one with mosaicism. Three cases had an EPHB4 variant of uncertain significance. The majority had epistaxis (6/10 cases) and telangiectasia (8/10 cases), as well as CMs. Two of ten cases had a central nervous system AVM.

CONCLUSIONS:

Our results emphasize the importance of considering CM-AVM2 as part of the clinical differential for HHT and other vascular malformation syndromes. Yet, these cases highlight significant differences in the cutaneous presentations of CM-AVM2 versus HHT.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Telangiectasia, Hereditary Hemorrhagic / Capillaries / Genetic Testing / Receptor, EphB4 / Vascular Malformations Type of study: Diagnostic_studies / Prognostic_studies Limits: Adolescent / Child / Female / Humans / Male Language: En Journal: Genet Med Journal subject: GENETICA MEDICA Year: 2019 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Telangiectasia, Hereditary Hemorrhagic / Capillaries / Genetic Testing / Receptor, EphB4 / Vascular Malformations Type of study: Diagnostic_studies / Prognostic_studies Limits: Adolescent / Child / Female / Humans / Male Language: En Journal: Genet Med Journal subject: GENETICA MEDICA Year: 2019 Document type: Article Affiliation country: United States
...